# Healthcare Triangle, Inc.: overview

HCTI · Nasdaq · CIK 1839285 · [Technology](/sectors/technology.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/hcti.md) · [Financials](/companies/hcti/financials.md) · [Filings](/companies/hcti/filings.md) · [Insiders](/companies/hcti/insiders.md)

Latest reported revenue: [$9.2m](/filings/0001213900-26-089241.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 13, 2026 (XBRL us-gaap:Revenues, accession 0001213900-26-089241).

## Last eight quarters

| Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $k | [2,413](/filings/0001213900-25-109581.md) | [2,190 d](/filings/0001213900-26-044671.md) | [3,704](/filings/0001213900-26-056096.md) | [3,558](/filings/0001213900-26-089241.md) | [3,489](/filings/0001213900-25-109581.md) | [3,139 d](/filings/0001213900-26-044671.md) | [9,855](/filings/0001213900-26-056096.md) | [9,193](/filings/0001213900-26-089241.md) |
| Gross margin | % | [0.0% d](/filings/0001213900-24-098548.md) | [0.0% d](/filings/0001213900-25-026218.md) | [28887.7%](/filings/0001213900-25-045994.md) | [13.9%](/filings/0001213900-26-089241.md) | [30644.2% d](/filings/0001213900-25-109581.md) | [5256.5% d](/filings/0001213900-26-044671.md) | not reported | [22.5%](/filings/0001213900-26-089241.md) |
| Operating margin | % | [(48.4%)](/filings/0001213900-25-109581.md) | [(22.7%) d](/filings/0001213900-26-044671.md) | [(37.7%)](/filings/0001213900-26-056096.md) | [(38.2%)](/filings/0001213900-26-089241.md) | [(74.3%)](/filings/0001213900-25-109581.md) | [(141.5%) d](/filings/0001213900-26-044671.md) | [(36.8%)](/filings/0001213900-26-056096.md) | [(44.3%)](/filings/0001213900-26-089241.md) |
| Net margin | % | [(51.8%)](/filings/0001213900-25-109581.md) | [(61.6%) d](/filings/0001213900-26-044671.md) | [(45.9%)](/filings/0001213900-26-056096.md) | [(38.4%)](/filings/0001213900-26-089241.md) | [(54.6%)](/filings/0001213900-25-109581.md) | [(143.5%) d](/filings/0001213900-26-044671.md) | [(62.9%)](/filings/0001213900-26-056096.md) | [(48.0%)](/filings/0001213900-26-089241.md) |
| Diluted EPS | $ per share | [(54.78)](/filings/0001213900-25-109581.md) | not reported | [(0.17)](/filings/0001213900-26-056096.md) | [(35.01)](/filings/0001213900-26-089241.md) | [(0.42)](/filings/0001213900-25-109581.md) | not reported | [(6.81)](/filings/0001213900-26-056096.md) | [(1.56)](/filings/0001213900-26-089241.md) |
| Free cash flow | $k | not reported | not reported | not reported | not reported | [(1,500) d](/filings/0001213900-25-109581.md) | [(6,834) d](/filings/0001213900-26-044671.md) | [(6,886)](/filings/0001213900-26-056096.md) | not reported |

- Revenue. XBRL Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure.
- Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:Revenues. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure.

## Last five fiscal years

| Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [35.3](/filings/0001607062-23-000154.md) | [45.9](/filings/0001213900-25-014503.md) | [33.2](/filings/0001213900-25-026218.md) | [11.7](/filings/0001213900-26-044671.md) | [13.9](/filings/0001213900-26-044671.md) |
| Gross margin | % | not reported | not reported | [3222.6%](/filings/0001213900-25-014503.md) | [9148.4%](/filings/0001213900-25-026218.md) | [8890.6%](/filings/0001213900-26-044671.md) |
| Operating margin | % | [(15.2%)](/filings/0001607062-23-000154.md) | [(35.6%)](/filings/0001213900-25-014503.md) | [(23.2%)](/filings/0001213900-25-026218.md) | [(40.6%)](/filings/0001213900-26-044671.md) | [(70.5%)](/filings/0001213900-26-044671.md) |
| Net margin | % | [(16.9%)](/filings/0001607062-23-000154.md) | [(31.3%)](/filings/0001213900-25-014503.md) | [(26.2%)](/filings/0001213900-25-026218.md) | [(51.0%)](/filings/0001213900-26-044671.md) | [(68.2%)](/filings/0001213900-26-044671.md) |
| Diluted EPS | $ per share | [(0.20)](/filings/0001607062-22-000176.md) | [(3.88)](/filings/0001213900-25-014503.md) | [(2.08)](/filings/0001213900-25-026218.md) | [(16909.30)](/filings/0001213900-26-044671.md) | [(152.30)](/filings/0001213900-26-044671.md) |
| Free cash flow | $m | not reported | [(5.4)](/filings/0001213900-25-014503.md) | [(2.2)](/filings/0001213900-25-026218.md) | not reported | [(16.5)](/filings/0001213900-26-044671.md) |

- Revenue. XBRL Revenue: us-gaap:Revenues.
- Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:Revenues; Gross profit: us-gaap:GrossProfit.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:Revenues.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:Revenues.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.

Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing.

## Insider purchases and sales

The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/hcti/insiders.md)

None in coverage.

## Funds that report holding it

From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md)

| Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before |
| --- | --- | ---: | ---: | --- | --- |
| [BANK OF MONTREAL /CAN/](/funds/927971.md) | 2026-06-30 | $36.2k | 20,000 |  | Added +10,000 |
| [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $21.7k | 11,975 |  | Reduced −620 |
| [UBS Group AG](/funds/1610520.md) | 2026-06-30 | $16.0k | 8,859 |  | Reduced −31,856 |
| [Tower Research Capital LLC (TRC)](/funds/1533421.md) | 2026-06-30 | $2.4k | 1,314 |  | Added +520 |
| [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $1.6k | 859 |  | Unchanged |
| [BARCLAYS PLC](/funds/312069.md) | 2026-06-30 | $561 | 310 |  | New +310 |
| [JPMORGAN CHASE & CO](/funds/19617.md) | 2026-06-30 | $38 | 20 |  | New +20 |
| [DANSKE BANK A/S](/funds/800177.md) | 2026-06-30 | $2 | 1 |  | Unchanged |

## Recent filings

[All 262 filings](/companies/hcti/filings.md)

| Filed | Accepted | Form | What it is | Accession |
| --- | --- | --- | --- | --- |
| 2026-10-23 | 17:20 ET | [8-K](/filings/0001213900-26-112193.md) | 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0001213900-26-112193 |
| 2026-10-13 | 17:20 ET | [DEF 14A](/filings/0001213900-26-109104.md) | Proxy statement, period 2026-10-23 | 0001213900-26-109104 |
| 2026-10-02 | 17:20 ET | [8-K](/filings/0001213900-26-106533.md) | 3.01 Delisting notice; 9.01 Financial statements and exhibits | 0001213900-26-106533 |
| 2026-09-25 | 17:15 ET | [8-K](/filings/0001213900-26-103604.md) | 1.01 Entry into a material agreement; 9.01 Financial statements and exhibits | 0001213900-26-103604 |
| 2026-09-08 | 13:56 ET | [8-K](/filings/0001213900-26-097953.md) | 1.01 Entry into a material agreement; 9.01 Financial statements and exhibits | 0001213900-26-097953 |
| 2026-08-13 | 17:16 ET | [10-Q](/filings/0001213900-26-089241.md) | Quarterly report, period 2026-06-30 | 0001213900-26-089241 |
| 2026-07-29 | 07:10 ET | [8-K](/filings/0001213900-26-082514.md) | 3.02 Unregistered sale of equity; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001213900-26-082514 |
| 2026-07-20 | 16:05 ET | [8-K](/filings/0001213900-26-079616.md) | 5.07 Shareholder vote results | 0001213900-26-079616 |
| 2026-07-10 | 17:15 ET | [S-1](/filings/0001213900-26-077268.md) | Registration statement | 0001213900-26-077268 |
| 2026-06-26 | 17:00 ET | [DEF 14A](/filings/0001213900-26-072691.md) | Proxy statement, period 2026-07-17 | 0001213900-26-072691 |

## Latest annual report

[Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001213900-26-044078.md), filed Apr 15, 2026.

## Forecast league

Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/e4b7258c-7b27-483c-9b05-c0dcf4eca01e)

## About the filer

- CIK: 1839285
- Tickers: HCTI
- Exchange: Nasdaq
- SIC code: 7373 Services-Computer Integrated Systems Design
- State of incorporation: DE
- Filer category: <br>Emerging growth company

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 27, 2026, 17:16 ET. No prices; not investment advice.